Efficacy of long‐term adrenocorticotropic hormone therapy for West syndrome: A retrospective multicenter case series
Objectives Long‐term adrenocorticotropic therapy (LT‐ACTH), which consisted of 2‐4 weeks of daily injections of adrenocorticotropic hormone (ACTH) and subsequent months of weekly injections, was tried for relapsed West syndrome (WS) or other intractable epilepsies in small case reports. Our aim was...
Gespeichert in:
Veröffentlicht in: | Epilepsia Open 2021-06, Vol.6 (2), p.402-412 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 412 |
---|---|
container_issue | 2 |
container_start_page | 402 |
container_title | Epilepsia Open |
container_volume | 6 |
creator | Baba, Shimpei Okanishi, Tohru Homma, Yoichiro Yoshida, Takeshi Goto, Tomohide Fukasawa, Tatsuya Kobayashi, Satoru Kamei, Atsushi Fujii, Yuji Hino‐Fukuyo, Naomi Yamada, Keitaro Daida, Atsuro Kawawaki, Hisashi Hoshino, Hideki Sejima, Hitoshi Ishida, Yusuke Okazaki, Tetsuya Inui, Takehiko Kanai, Sotaro Motoi, Hirotaka Itamura, Shinji Nishimura, Mitsuyo Enoki, Hideo Fujimoto, Ayataka |
description | Objectives
Long‐term adrenocorticotropic therapy (LT‐ACTH), which consisted of 2‐4 weeks of daily injections of adrenocorticotropic hormone (ACTH) and subsequent months of weekly injections, was tried for relapsed West syndrome (WS) or other intractable epilepsies in small case reports. Our aim was to explore the efficacy of LT‐ACTH for preventing WS relapse, as well as the prevalence of its adverse events.
Methods
This is a retrospective, nationwide, multicenter case series of patients with WS who underwent LT‐ACTH. Clinical information of the patients and protocol of LT‐ACTH were collected from participating institutes in this study. We defined clinical response to ACTH as achievement of hypsarrhythmia and epileptic spasms resolution. Patients who responded to daily ACTH injections were identified and assessed whether they experienced WS relapse during/after the weekly ACTH injection period. The outcome was measured by the nonrelapse rate at 24 months after daily ACTH injections using the Kaplan‐Meier method.
Results
Clinical information of 16 children with WS was analyzed. The median age at LT‐ACTH initiation was 14.5 months (range: 7‐68 months). Thirteen (81%) patients had previously undergone conventional ACTH treatment. The LT‐ACTH regimens comprised a median of 16 days of daily injections (range: 11‐28 days) and 10 months of weekly injections (range: 3‐22 months). Seven patients experienced WS relapse during/after subsequent weekly ACTH period, and the nonrelapse rate at 24 months after daily injections was estimated at 60.6% (95% confidence interval: 32.3%‐80.0%). Height stagnation, hypertension, and irritability were observed; lethal adverse events were not reported.
Significance
Our study firstly explored the efficacy of LT‐ACTH for preventing WS relapse. LT‐ACTH might be a treatment option for patients with relapsed or intractable WS; however, we note that our study is limited by its small sample size and the lack of an appropriate control group. |
doi_str_mv | 10.1002/epi4.12497 |
format | Article |
fullrecord | <record><control><sourceid>gale_webof</sourceid><recordid>TN_cdi_webofscience_primary_000657725200001</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A710998850</galeid><doaj_id>oai_doaj_org_article_56142fc7aa2543ce9e1f76d9d0a1ecd0</doaj_id><sourcerecordid>A710998850</sourcerecordid><originalsourceid>FETCH-LOGICAL-c6477-3c5b65beeac4122f1eb653f415e95631327886dc603b42e72fe8984ecca914ab3</originalsourceid><addsrcrecordid>eNqNks2O0zAUhSMEYkbDbHgAZIkdqMV2_BOzQKqqApVGggWIpeU4161HjR2ctKg7HoFn5ElwJqWa2SBWSZzvHp1zfYriOcFzgjF9A51nc0KZko-KS8oknilaqsf33i-K676_xRgTRQkR-GlxUTKsuKjEZXFYOeetsUcUHdrFsPn989cAqUWmSRCijWnwNg4pdt6ibUxtDICGLSTTHZGLCX2DfkD9MTQptvAWLVCCTPcd2MEfALX7XRaAkDWRNT2gHpKH_lnxxJldD9en51Xx9f3qy_Lj7ObTh_VycTOzgkk5Ky2vBa8BjGWEUkcgf5aOEQ7Zf0lKKqtKNFbgsmYUJHVQqYqBtUYRZuryqlhPuk00t7pLvjXpqKPx-u4gpo02Y8IdaC4Io85KYyhnpQUFxEnRqAYbArbBWevdpNXt6xaaMVQyuweiD_8Ev9WbeNAVEUIqkQVengRS_L7Pe9O3cZ9Czq8pL5lUinKeqflEbUx25YPL2zf5hkwDbb6KAM7n84UkWKmq4qOvV9OAzXvvE7izJYL12BE9dkTfdSTDL-6HOKN_G5GBagJ-QB1dbz0EC2cst0hwKSmneCzU0g9m8DEs4z4MefT1_49mmpzonOf4D8969XnNJvd_AORh6o8</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2534799255</pqid></control><display><type>article</type><title>Efficacy of long‐term adrenocorticotropic hormone therapy for West syndrome: A retrospective multicenter case series</title><source>Access via Wiley Online Library</source><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Web of Science - Science Citation Index Expanded - 2021<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" /></source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Wiley Online Library (Open Access Collection)</source><source>PubMed Central</source><creator>Baba, Shimpei ; Okanishi, Tohru ; Homma, Yoichiro ; Yoshida, Takeshi ; Goto, Tomohide ; Fukasawa, Tatsuya ; Kobayashi, Satoru ; Kamei, Atsushi ; Fujii, Yuji ; Hino‐Fukuyo, Naomi ; Yamada, Keitaro ; Daida, Atsuro ; Kawawaki, Hisashi ; Hoshino, Hideki ; Sejima, Hitoshi ; Ishida, Yusuke ; Okazaki, Tetsuya ; Inui, Takehiko ; Kanai, Sotaro ; Motoi, Hirotaka ; Itamura, Shinji ; Nishimura, Mitsuyo ; Enoki, Hideo ; Fujimoto, Ayataka</creator><creatorcontrib>Baba, Shimpei ; Okanishi, Tohru ; Homma, Yoichiro ; Yoshida, Takeshi ; Goto, Tomohide ; Fukasawa, Tatsuya ; Kobayashi, Satoru ; Kamei, Atsushi ; Fujii, Yuji ; Hino‐Fukuyo, Naomi ; Yamada, Keitaro ; Daida, Atsuro ; Kawawaki, Hisashi ; Hoshino, Hideki ; Sejima, Hitoshi ; Ishida, Yusuke ; Okazaki, Tetsuya ; Inui, Takehiko ; Kanai, Sotaro ; Motoi, Hirotaka ; Itamura, Shinji ; Nishimura, Mitsuyo ; Enoki, Hideo ; Fujimoto, Ayataka</creatorcontrib><description>Objectives
Long‐term adrenocorticotropic therapy (LT‐ACTH), which consisted of 2‐4 weeks of daily injections of adrenocorticotropic hormone (ACTH) and subsequent months of weekly injections, was tried for relapsed West syndrome (WS) or other intractable epilepsies in small case reports. Our aim was to explore the efficacy of LT‐ACTH for preventing WS relapse, as well as the prevalence of its adverse events.
Methods
This is a retrospective, nationwide, multicenter case series of patients with WS who underwent LT‐ACTH. Clinical information of the patients and protocol of LT‐ACTH were collected from participating institutes in this study. We defined clinical response to ACTH as achievement of hypsarrhythmia and epileptic spasms resolution. Patients who responded to daily ACTH injections were identified and assessed whether they experienced WS relapse during/after the weekly ACTH injection period. The outcome was measured by the nonrelapse rate at 24 months after daily ACTH injections using the Kaplan‐Meier method.
Results
Clinical information of 16 children with WS was analyzed. The median age at LT‐ACTH initiation was 14.5 months (range: 7‐68 months). Thirteen (81%) patients had previously undergone conventional ACTH treatment. The LT‐ACTH regimens comprised a median of 16 days of daily injections (range: 11‐28 days) and 10 months of weekly injections (range: 3‐22 months). Seven patients experienced WS relapse during/after subsequent weekly ACTH period, and the nonrelapse rate at 24 months after daily injections was estimated at 60.6% (95% confidence interval: 32.3%‐80.0%). Height stagnation, hypertension, and irritability were observed; lethal adverse events were not reported.
Significance
Our study firstly explored the efficacy of LT‐ACTH for preventing WS relapse. LT‐ACTH might be a treatment option for patients with relapsed or intractable WS; however, we note that our study is limited by its small sample size and the lack of an appropriate control group.</description><identifier>ISSN: 2470-9239</identifier><identifier>EISSN: 2470-9239</identifier><identifier>DOI: 10.1002/epi4.12497</identifier><identifier>PMID: 34095686</identifier><language>eng</language><publisher>HOBOKEN: Wiley</publisher><subject>ACTH ; adrenocorticotropic hormone ; Adrenocorticotropic Hormone - adverse effects ; Adrenocorticotropic Hormone - therapeutic use ; Analysis ; Care and treatment ; Child ; Clinical Neurology ; Convulsions & seizures ; Drug dosages ; Electroencephalography ; Endocrine therapy ; Epilepsy ; Full‐length Original Research ; Humans ; Hypertension ; Life Sciences & Biomedicine ; long‐term treatment ; Metabolism ; Nationwide survey ; Neurosciences ; Neurosciences & Neurology ; Patients ; Pediatrics ; Questionnaires ; Recurrence ; retrospective case series ; Retrospective Studies ; Science & Technology ; Spasms, Infantile - drug therapy ; West syndrome</subject><ispartof>Epilepsia Open, 2021-06, Vol.6 (2), p.402-412</ispartof><rights>2021 The Authors. published by Wiley Periodicals LLC on behalf of International League Against Epilepsy</rights><rights>2021 The Authors. Epilepsia Open published by Wiley Periodicals LLC on behalf of International League Against Epilepsy.</rights><rights>COPYRIGHT 2021 John Wiley & Sons, Inc.</rights><rights>2021. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>true</woscitedreferencessubscribed><woscitedreferencescount>7</woscitedreferencescount><woscitedreferencesoriginalsourcerecordid>wos000657725200001</woscitedreferencesoriginalsourcerecordid><citedby>FETCH-LOGICAL-c6477-3c5b65beeac4122f1eb653f415e95631327886dc603b42e72fe8984ecca914ab3</citedby><cites>FETCH-LOGICAL-c6477-3c5b65beeac4122f1eb653f415e95631327886dc603b42e72fe8984ecca914ab3</cites><orcidid>0000-0002-0596-3338 ; 0000-0002-3017-9078 ; 0000-0003-0992-064X ; 0000-0002-7320-2346 ; 0000-0002-5308-2965 ; 0000-0003-3842-9294 ; 0000-0003-3295-2236 ; 0000-0003-1350-7700</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8166796/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8166796/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,315,729,782,786,866,887,1419,2106,2118,11571,27933,27934,39267,45583,45584,46061,46485,53800,53802</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34095686$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Baba, Shimpei</creatorcontrib><creatorcontrib>Okanishi, Tohru</creatorcontrib><creatorcontrib>Homma, Yoichiro</creatorcontrib><creatorcontrib>Yoshida, Takeshi</creatorcontrib><creatorcontrib>Goto, Tomohide</creatorcontrib><creatorcontrib>Fukasawa, Tatsuya</creatorcontrib><creatorcontrib>Kobayashi, Satoru</creatorcontrib><creatorcontrib>Kamei, Atsushi</creatorcontrib><creatorcontrib>Fujii, Yuji</creatorcontrib><creatorcontrib>Hino‐Fukuyo, Naomi</creatorcontrib><creatorcontrib>Yamada, Keitaro</creatorcontrib><creatorcontrib>Daida, Atsuro</creatorcontrib><creatorcontrib>Kawawaki, Hisashi</creatorcontrib><creatorcontrib>Hoshino, Hideki</creatorcontrib><creatorcontrib>Sejima, Hitoshi</creatorcontrib><creatorcontrib>Ishida, Yusuke</creatorcontrib><creatorcontrib>Okazaki, Tetsuya</creatorcontrib><creatorcontrib>Inui, Takehiko</creatorcontrib><creatorcontrib>Kanai, Sotaro</creatorcontrib><creatorcontrib>Motoi, Hirotaka</creatorcontrib><creatorcontrib>Itamura, Shinji</creatorcontrib><creatorcontrib>Nishimura, Mitsuyo</creatorcontrib><creatorcontrib>Enoki, Hideo</creatorcontrib><creatorcontrib>Fujimoto, Ayataka</creatorcontrib><title>Efficacy of long‐term adrenocorticotropic hormone therapy for West syndrome: A retrospective multicenter case series</title><title>Epilepsia Open</title><addtitle>EPILEPSIA OPEN</addtitle><addtitle>Epilepsia Open</addtitle><description>Objectives
Long‐term adrenocorticotropic therapy (LT‐ACTH), which consisted of 2‐4 weeks of daily injections of adrenocorticotropic hormone (ACTH) and subsequent months of weekly injections, was tried for relapsed West syndrome (WS) or other intractable epilepsies in small case reports. Our aim was to explore the efficacy of LT‐ACTH for preventing WS relapse, as well as the prevalence of its adverse events.
Methods
This is a retrospective, nationwide, multicenter case series of patients with WS who underwent LT‐ACTH. Clinical information of the patients and protocol of LT‐ACTH were collected from participating institutes in this study. We defined clinical response to ACTH as achievement of hypsarrhythmia and epileptic spasms resolution. Patients who responded to daily ACTH injections were identified and assessed whether they experienced WS relapse during/after the weekly ACTH injection period. The outcome was measured by the nonrelapse rate at 24 months after daily ACTH injections using the Kaplan‐Meier method.
Results
Clinical information of 16 children with WS was analyzed. The median age at LT‐ACTH initiation was 14.5 months (range: 7‐68 months). Thirteen (81%) patients had previously undergone conventional ACTH treatment. The LT‐ACTH regimens comprised a median of 16 days of daily injections (range: 11‐28 days) and 10 months of weekly injections (range: 3‐22 months). Seven patients experienced WS relapse during/after subsequent weekly ACTH period, and the nonrelapse rate at 24 months after daily injections was estimated at 60.6% (95% confidence interval: 32.3%‐80.0%). Height stagnation, hypertension, and irritability were observed; lethal adverse events were not reported.
Significance
Our study firstly explored the efficacy of LT‐ACTH for preventing WS relapse. LT‐ACTH might be a treatment option for patients with relapsed or intractable WS; however, we note that our study is limited by its small sample size and the lack of an appropriate control group.</description><subject>ACTH</subject><subject>adrenocorticotropic hormone</subject><subject>Adrenocorticotropic Hormone - adverse effects</subject><subject>Adrenocorticotropic Hormone - therapeutic use</subject><subject>Analysis</subject><subject>Care and treatment</subject><subject>Child</subject><subject>Clinical Neurology</subject><subject>Convulsions & seizures</subject><subject>Drug dosages</subject><subject>Electroencephalography</subject><subject>Endocrine therapy</subject><subject>Epilepsy</subject><subject>Full‐length Original Research</subject><subject>Humans</subject><subject>Hypertension</subject><subject>Life Sciences & Biomedicine</subject><subject>long‐term treatment</subject><subject>Metabolism</subject><subject>Nationwide survey</subject><subject>Neurosciences</subject><subject>Neurosciences & Neurology</subject><subject>Patients</subject><subject>Pediatrics</subject><subject>Questionnaires</subject><subject>Recurrence</subject><subject>retrospective case series</subject><subject>Retrospective Studies</subject><subject>Science & Technology</subject><subject>Spasms, Infantile - drug therapy</subject><subject>West syndrome</subject><issn>2470-9239</issn><issn>2470-9239</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>WIN</sourceid><sourceid>HGBXW</sourceid><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>DOA</sourceid><recordid>eNqNks2O0zAUhSMEYkbDbHgAZIkdqMV2_BOzQKqqApVGggWIpeU4161HjR2ctKg7HoFn5ElwJqWa2SBWSZzvHp1zfYriOcFzgjF9A51nc0KZko-KS8oknilaqsf33i-K676_xRgTRQkR-GlxUTKsuKjEZXFYOeetsUcUHdrFsPn989cAqUWmSRCijWnwNg4pdt6ibUxtDICGLSTTHZGLCX2DfkD9MTQptvAWLVCCTPcd2MEfALX7XRaAkDWRNT2gHpKH_lnxxJldD9en51Xx9f3qy_Lj7ObTh_VycTOzgkk5Ky2vBa8BjGWEUkcgf5aOEQ7Zf0lKKqtKNFbgsmYUJHVQqYqBtUYRZuryqlhPuk00t7pLvjXpqKPx-u4gpo02Y8IdaC4Io85KYyhnpQUFxEnRqAYbArbBWevdpNXt6xaaMVQyuweiD_8Ev9WbeNAVEUIqkQVengRS_L7Pe9O3cZ9Czq8pL5lUinKeqflEbUx25YPL2zf5hkwDbb6KAM7n84UkWKmq4qOvV9OAzXvvE7izJYL12BE9dkTfdSTDL-6HOKN_G5GBagJ-QB1dbz0EC2cst0hwKSmneCzU0g9m8DEs4z4MefT1_49mmpzonOf4D8969XnNJvd_AORh6o8</recordid><startdate>202106</startdate><enddate>202106</enddate><creator>Baba, Shimpei</creator><creator>Okanishi, Tohru</creator><creator>Homma, Yoichiro</creator><creator>Yoshida, Takeshi</creator><creator>Goto, Tomohide</creator><creator>Fukasawa, Tatsuya</creator><creator>Kobayashi, Satoru</creator><creator>Kamei, Atsushi</creator><creator>Fujii, Yuji</creator><creator>Hino‐Fukuyo, Naomi</creator><creator>Yamada, Keitaro</creator><creator>Daida, Atsuro</creator><creator>Kawawaki, Hisashi</creator><creator>Hoshino, Hideki</creator><creator>Sejima, Hitoshi</creator><creator>Ishida, Yusuke</creator><creator>Okazaki, Tetsuya</creator><creator>Inui, Takehiko</creator><creator>Kanai, Sotaro</creator><creator>Motoi, Hirotaka</creator><creator>Itamura, Shinji</creator><creator>Nishimura, Mitsuyo</creator><creator>Enoki, Hideo</creator><creator>Fujimoto, Ayataka</creator><general>Wiley</general><general>John Wiley & Sons, Inc</general><general>John Wiley and Sons Inc</general><scope>24P</scope><scope>WIN</scope><scope>BLEPL</scope><scope>DTL</scope><scope>HGBXW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IAO</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-0596-3338</orcidid><orcidid>https://orcid.org/0000-0002-3017-9078</orcidid><orcidid>https://orcid.org/0000-0003-0992-064X</orcidid><orcidid>https://orcid.org/0000-0002-7320-2346</orcidid><orcidid>https://orcid.org/0000-0002-5308-2965</orcidid><orcidid>https://orcid.org/0000-0003-3842-9294</orcidid><orcidid>https://orcid.org/0000-0003-3295-2236</orcidid><orcidid>https://orcid.org/0000-0003-1350-7700</orcidid></search><sort><creationdate>202106</creationdate><title>Efficacy of long‐term adrenocorticotropic hormone therapy for West syndrome: A retrospective multicenter case series</title><author>Baba, Shimpei ; Okanishi, Tohru ; Homma, Yoichiro ; Yoshida, Takeshi ; Goto, Tomohide ; Fukasawa, Tatsuya ; Kobayashi, Satoru ; Kamei, Atsushi ; Fujii, Yuji ; Hino‐Fukuyo, Naomi ; Yamada, Keitaro ; Daida, Atsuro ; Kawawaki, Hisashi ; Hoshino, Hideki ; Sejima, Hitoshi ; Ishida, Yusuke ; Okazaki, Tetsuya ; Inui, Takehiko ; Kanai, Sotaro ; Motoi, Hirotaka ; Itamura, Shinji ; Nishimura, Mitsuyo ; Enoki, Hideo ; Fujimoto, Ayataka</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c6477-3c5b65beeac4122f1eb653f415e95631327886dc603b42e72fe8984ecca914ab3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>ACTH</topic><topic>adrenocorticotropic hormone</topic><topic>Adrenocorticotropic Hormone - adverse effects</topic><topic>Adrenocorticotropic Hormone - therapeutic use</topic><topic>Analysis</topic><topic>Care and treatment</topic><topic>Child</topic><topic>Clinical Neurology</topic><topic>Convulsions & seizures</topic><topic>Drug dosages</topic><topic>Electroencephalography</topic><topic>Endocrine therapy</topic><topic>Epilepsy</topic><topic>Full‐length Original Research</topic><topic>Humans</topic><topic>Hypertension</topic><topic>Life Sciences & Biomedicine</topic><topic>long‐term treatment</topic><topic>Metabolism</topic><topic>Nationwide survey</topic><topic>Neurosciences</topic><topic>Neurosciences & Neurology</topic><topic>Patients</topic><topic>Pediatrics</topic><topic>Questionnaires</topic><topic>Recurrence</topic><topic>retrospective case series</topic><topic>Retrospective Studies</topic><topic>Science & Technology</topic><topic>Spasms, Infantile - drug therapy</topic><topic>West syndrome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Baba, Shimpei</creatorcontrib><creatorcontrib>Okanishi, Tohru</creatorcontrib><creatorcontrib>Homma, Yoichiro</creatorcontrib><creatorcontrib>Yoshida, Takeshi</creatorcontrib><creatorcontrib>Goto, Tomohide</creatorcontrib><creatorcontrib>Fukasawa, Tatsuya</creatorcontrib><creatorcontrib>Kobayashi, Satoru</creatorcontrib><creatorcontrib>Kamei, Atsushi</creatorcontrib><creatorcontrib>Fujii, Yuji</creatorcontrib><creatorcontrib>Hino‐Fukuyo, Naomi</creatorcontrib><creatorcontrib>Yamada, Keitaro</creatorcontrib><creatorcontrib>Daida, Atsuro</creatorcontrib><creatorcontrib>Kawawaki, Hisashi</creatorcontrib><creatorcontrib>Hoshino, Hideki</creatorcontrib><creatorcontrib>Sejima, Hitoshi</creatorcontrib><creatorcontrib>Ishida, Yusuke</creatorcontrib><creatorcontrib>Okazaki, Tetsuya</creatorcontrib><creatorcontrib>Inui, Takehiko</creatorcontrib><creatorcontrib>Kanai, Sotaro</creatorcontrib><creatorcontrib>Motoi, Hirotaka</creatorcontrib><creatorcontrib>Itamura, Shinji</creatorcontrib><creatorcontrib>Nishimura, Mitsuyo</creatorcontrib><creatorcontrib>Enoki, Hideo</creatorcontrib><creatorcontrib>Fujimoto, Ayataka</creatorcontrib><collection>Wiley Online Library (Open Access Collection)</collection><collection>Wiley Online Library (Open Access Collection)</collection><collection>Web of Science Core Collection</collection><collection>Science Citation Index Expanded</collection><collection>Web of Science - Science Citation Index Expanded - 2021</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale Academic OneFile</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Access via ProQuest (Open Access)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Epilepsia Open</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Baba, Shimpei</au><au>Okanishi, Tohru</au><au>Homma, Yoichiro</au><au>Yoshida, Takeshi</au><au>Goto, Tomohide</au><au>Fukasawa, Tatsuya</au><au>Kobayashi, Satoru</au><au>Kamei, Atsushi</au><au>Fujii, Yuji</au><au>Hino‐Fukuyo, Naomi</au><au>Yamada, Keitaro</au><au>Daida, Atsuro</au><au>Kawawaki, Hisashi</au><au>Hoshino, Hideki</au><au>Sejima, Hitoshi</au><au>Ishida, Yusuke</au><au>Okazaki, Tetsuya</au><au>Inui, Takehiko</au><au>Kanai, Sotaro</au><au>Motoi, Hirotaka</au><au>Itamura, Shinji</au><au>Nishimura, Mitsuyo</au><au>Enoki, Hideo</au><au>Fujimoto, Ayataka</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy of long‐term adrenocorticotropic hormone therapy for West syndrome: A retrospective multicenter case series</atitle><jtitle>Epilepsia Open</jtitle><stitle>EPILEPSIA OPEN</stitle><addtitle>Epilepsia Open</addtitle><date>2021-06</date><risdate>2021</risdate><volume>6</volume><issue>2</issue><spage>402</spage><epage>412</epage><pages>402-412</pages><issn>2470-9239</issn><eissn>2470-9239</eissn><abstract>Objectives
Long‐term adrenocorticotropic therapy (LT‐ACTH), which consisted of 2‐4 weeks of daily injections of adrenocorticotropic hormone (ACTH) and subsequent months of weekly injections, was tried for relapsed West syndrome (WS) or other intractable epilepsies in small case reports. Our aim was to explore the efficacy of LT‐ACTH for preventing WS relapse, as well as the prevalence of its adverse events.
Methods
This is a retrospective, nationwide, multicenter case series of patients with WS who underwent LT‐ACTH. Clinical information of the patients and protocol of LT‐ACTH were collected from participating institutes in this study. We defined clinical response to ACTH as achievement of hypsarrhythmia and epileptic spasms resolution. Patients who responded to daily ACTH injections were identified and assessed whether they experienced WS relapse during/after the weekly ACTH injection period. The outcome was measured by the nonrelapse rate at 24 months after daily ACTH injections using the Kaplan‐Meier method.
Results
Clinical information of 16 children with WS was analyzed. The median age at LT‐ACTH initiation was 14.5 months (range: 7‐68 months). Thirteen (81%) patients had previously undergone conventional ACTH treatment. The LT‐ACTH regimens comprised a median of 16 days of daily injections (range: 11‐28 days) and 10 months of weekly injections (range: 3‐22 months). Seven patients experienced WS relapse during/after subsequent weekly ACTH period, and the nonrelapse rate at 24 months after daily injections was estimated at 60.6% (95% confidence interval: 32.3%‐80.0%). Height stagnation, hypertension, and irritability were observed; lethal adverse events were not reported.
Significance
Our study firstly explored the efficacy of LT‐ACTH for preventing WS relapse. LT‐ACTH might be a treatment option for patients with relapsed or intractable WS; however, we note that our study is limited by its small sample size and the lack of an appropriate control group.</abstract><cop>HOBOKEN</cop><pub>Wiley</pub><pmid>34095686</pmid><doi>10.1002/epi4.12497</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0002-0596-3338</orcidid><orcidid>https://orcid.org/0000-0002-3017-9078</orcidid><orcidid>https://orcid.org/0000-0003-0992-064X</orcidid><orcidid>https://orcid.org/0000-0002-7320-2346</orcidid><orcidid>https://orcid.org/0000-0002-5308-2965</orcidid><orcidid>https://orcid.org/0000-0003-3842-9294</orcidid><orcidid>https://orcid.org/0000-0003-3295-2236</orcidid><orcidid>https://orcid.org/0000-0003-1350-7700</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2470-9239 |
ispartof | Epilepsia Open, 2021-06, Vol.6 (2), p.402-412 |
issn | 2470-9239 2470-9239 |
language | eng |
recordid | cdi_webofscience_primary_000657725200001 |
source | Access via Wiley Online Library; MEDLINE; DOAJ Directory of Open Access Journals; Web of Science - Science Citation Index Expanded - 2021<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" />; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Wiley Online Library (Open Access Collection); PubMed Central |
subjects | ACTH adrenocorticotropic hormone Adrenocorticotropic Hormone - adverse effects Adrenocorticotropic Hormone - therapeutic use Analysis Care and treatment Child Clinical Neurology Convulsions & seizures Drug dosages Electroencephalography Endocrine therapy Epilepsy Full‐length Original Research Humans Hypertension Life Sciences & Biomedicine long‐term treatment Metabolism Nationwide survey Neurosciences Neurosciences & Neurology Patients Pediatrics Questionnaires Recurrence retrospective case series Retrospective Studies Science & Technology Spasms, Infantile - drug therapy West syndrome |
title | Efficacy of long‐term adrenocorticotropic hormone therapy for West syndrome: A retrospective multicenter case series |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-01T13%3A39%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_webof&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20of%20long%E2%80%90term%20adrenocorticotropic%20hormone%20therapy%20for%20West%20syndrome:%20A%20retrospective%20multicenter%20case%20series&rft.jtitle=Epilepsia%20Open&rft.au=Baba,%20Shimpei&rft.date=2021-06&rft.volume=6&rft.issue=2&rft.spage=402&rft.epage=412&rft.pages=402-412&rft.issn=2470-9239&rft.eissn=2470-9239&rft_id=info:doi/10.1002/epi4.12497&rft_dat=%3Cgale_webof%3EA710998850%3C/gale_webof%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2534799255&rft_id=info:pmid/34095686&rft_galeid=A710998850&rft_doaj_id=oai_doaj_org_article_56142fc7aa2543ce9e1f76d9d0a1ecd0&rfr_iscdi=true |